Structure Therapeutics (GPCR) Preferred Stock Liabilities (2022)

Structure Therapeutics (GPCR) recorded quarterly Preferred Stock Liabilities of $200.0 million in Q4 2022.

Structure Therapeutics (GPCR) Preferred Stock Liabilities (2022) Analysis & Trends

Structure Therapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $200.0 million for Q4 2022.

In Q4 2022, Preferred Stock Liabilities changed N/A year-over-year to $200.0 million; the TTM figure through Dec 2022 stood at $200.0 million (changed N/A YoY), while the FY2022 annual figure was $200.0 million, changed N/A from the prior year.
Preferred Stock Liabilities was $200.0 million for Q4 2022 at Structure Therapeutics.
In the past five years, Preferred Stock Liabilities ranged from a high of $200.0 million in Q4 2022 to a low of $200.0 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	-
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Structure Therapeutics	9.35 Bn	9.35 Bn	-	-

Download Data

Date	Value
Dec 31, 2022	199.98 Mn